Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, The University of Gothenburg, Mölndal, Sweden.
Acta Neurol Scand. 2018 Aug;138(2):143-150. doi: 10.1111/ane.12927. Epub 2018 Apr 6.
Although the recovery from Guillain-Barré syndrome (GBS) is good in most patients, some develop permanent severe disability or even die. Early predictors would increase the likelihood to identify patients at risk for poor outcome at the acute stage, allowing them intensified therapeutic intervention.
Eighteen patients with a history of GBS 9-17 years ago were reassessed with scoring of neurological disability and quality of life assessment (QoL). Their previous diagnostic work-up included clinical examination with scoring of disability, neurophysiological investigation, a battery of serology tests for infections, and cerebrospinal fluid (CSF) examination. Aliquots of CSF were frozen, stored for 20-28 years, and analyzed by ELISA for determination of neurofilament light protein (NFL) and glial fibrillary acidic protein (GFAP).
Patients with poor outcome (n = 3) had significantly higher NFL and GFAP levels at GBS nadir than those with good outcome (n = 15, P < .01 and P < .05, respectively). High NFL correlated with more prominent disability and worse QoL at long-term follow-up (r = .694, P < .001, and SF 36 dimension physical component summary (PCS) (r =-.65, P < .05), respectively, whereas GFAP did not correlate with clinical outcome or QoL.
High NFL in CSF at the acute stage of GBS seems to predict long-term outcome and might, together with neurophysiological and clinical measures, be useful in treatment decisions and clinical care of GBS.
尽管大多数吉兰-巴雷综合征(GBS)患者的恢复情况良好,但仍有部分患者会出现永久性严重残疾甚至死亡。早期预测因素可提高在急性阶段识别预后不良患者的可能性,从而使他们能够接受强化治疗干预。
18 名患者在 9-17 年前曾患有 GBS,现重新进行神经功能障碍评分和生活质量评估(QoL)。他们之前的诊断检查包括临床检查,神经功能障碍评分,一系列感染的血清学检查,以及脑脊液(CSF)检查。CSF 的等分试样被冷冻保存 20-28 年,然后通过 ELISA 分析测定神经丝轻蛋白(NFL)和胶质纤维酸性蛋白(GFAP)。
预后不良的患者(n=3)在 GBS 最低点时的 NFL 和 GFAP 水平明显高于预后良好的患者(n=15,P<0.01 和 P<0.05)。高 NFL 与长期随访时更明显的残疾和更差的 QoL 相关(r=0.694,P<0.001,SF 36 维度身体成分综合评分(PCS)(r=-.65,P<0.05),而 GFAP 与临床结果或 QoL 无相关性。
GBS 急性阶段 CSF 中的高 NFL 似乎可以预测长期预后,并且可能与神经生理学和临床措施一起,对 GBS 的治疗决策和临床护理有用。